Cadila Healthcare Ltd - 532321 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Zydus Announces Settlement of Patent Litigation for Generic Revlimid(r) in U.S.'.24-03-2021
24-03-2021
CADILA HEALTHCARE LTD. - 532321 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Information of loss of share certificate and request for issue of duplicate share certificate27-02-2021
CADILA HEALTHCARE LTD. - 532321 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Managing Director of the Company is going to participate in a panel discussion organized by Antique Broking on the theme 'Advantage India Pharma' tomorrow i.e. 26th February, 2021.25-02-2021
India has becomes the first to act on non-alcoholic fatty liver disease: Sharvil Patel
Zydus Cadila MD explains how his company's drug Saroglitazar Mg in significant in treating the disease25-02-2021
CADILA HEALTHCARE LTD. - 532321 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Zydus Cadila receives final approval from USFDA for Nortriptyline Hydrochloride Capsules25-02-2021
CADILA HEALTHCARE LTD. - 532321 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Sentynl Therapeutics' Asset Purchase Agreement for Cyprium Therapeutics' Copper Histidinate Product Candidate for Treatment of Menkes Disease24-02-2021
CADILA HEALTHCARE LTD. - 532321 - Announcement under Regulation 30 (LODR)-Investor Presentation
The Company is going to participate in IIFL's XII Enterprising India Conference, 2021 tomorrow i.e. 25th February, 2021.24-02-2021
Indian pharma goes local for APIs, strives to end dependence on China
"Because of the anti-China sentiment, most of the companies are working towards de-risking themselves in terms of making it clear that their supply chain linkages with China are limited," says Gaurav Suchak, supply head of Cadila23-02-2021
Cadila Healthcare stock trades lower even after USFDA nod for blood pressure drug
The drug will be manufactured at the group's formulation facility in Ahmedabad.19-02-2021
CADILA HEALTHCARE LTD. - 532321 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Zydus Cadila receives final approval from USFDA for Droxidopa Capsules.19-02-2021